¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"carcinoma dose"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® embryonal carcinoma ÇÑ±Û ¹è¾Æ¾ÏÁ¾
¼³¸í   
  »ý½Ä¼¼Æ÷¿¡¼­ »ý±â´Â ¾ÏÁ¾ÀÇ Çϳª·Î ´ëºÎºÐ °íȯ¿¡¼­ ¹ß»ýÇÑ´Ù. µå¹°°Ô´Â Á¾°Ýµ¿¿¡¼­µµ ¹ß»ýÇÑ´Ù. 40~50´ëÀÇ ³²¼º¿¡°Ô ¸¹À¸³ª, À̺¸´Ù ³·Àº ¿¬·ÉÃþ¿¡¼­µµ ³ªÅ¸³­´Ù. À°¾ÈÀûÀ¸·Î´Â È¸¹é»öÀÇ ºÐ¿±À» º¸À̴ µ¢¾î¸®¸¦ Çü¼ºÇϸç, °íȯ ¾Ç¼º Á¾¾ç Áß ¿¹Èİ¡ ÁÁÀº ÆíÀÌ´Ù. Ä¡·áÀÇ ¿øÄ¢Àº °¡±ÞÀû ½Å¼ÓÇϰԠ¿ø¹ß¼Ò¸¦ ÀýÁ¦ÇÏ°í ¿¹»óµÇ´Â ÀüÀ̺´ÅÍ¿¡ ´ëÇÏ¿© ¹æ»ç¼± Á¶»ç¿ä¹ýÀ» ÇàÇØ¾ß ÇÑ´Ù. Å»ý¾ÏÁ¾ ¹æ»ç¼±¿ä¹ý¿¡ ´ëÇÏ¿© ¸Å¿ì °¨¼ö¼ºÀÌ ³ô±â ¶§¹®¿¡ º´±â°¡ ÃʱâÀ̸é 90% ÀÌ»óÀÇ Ä¡·á°¡ ±â´ëµÈ´Ù. ±×¸®°í È­Çпä¹ýÁ¦¿¡ ÀÇÇØ ±× Ä¡·á¼º°ú°¡ »ó½ÂÇϰí ÀÖ´Ù.
¿µ¹® carcinoma in situ ÇÑ±Û »óÇdz»¾ÏÁ¾
¼³¸í   
  ½ÅüÀÇ ³»ºÎ³ª ¿ÜºÎ¸¦ ½×°í Àִ Á¶Á÷À» »óÇǶó°í ÇÑ´Ù. ÀÌ »óÇÇÀÇ ¾Æ·¡¿¡´Â ´ë°³ »óÇǸ¦ ÁöÁöÇϰí Àִ Á¶Á÷ÀÇ À§¿¡ Á¸ÀçÇÑ´Ù. ±×¸®°í ÀÌ ÁöÁöÁ¶Á÷°ú »óÇÇ »çÀÌ¿¡´Â ±âÀú¸·À̶ó´Â ¸·ÀÌ À־ »óÇǿ͠ÁöÁöÁ¶Á÷À» ±¸ºÐÇØ ÁØ´Ù. ¾ÏÁ¾(carcinoma)¶õ »óÇÇÀÇ ¼¼Æ÷°¡ ¾Ç¼º º¯È­¸¦ ÇÏ¿© »ý±â´Â ¾ÏÀ» ¸»ÇÑ´Ù. Á¦ÀÚ¸®¾ÏÁ¾À̶õ ¾ÏÁ¾ÀÇ ÇÑ Á¾·ù·Î ¾ÏÁ¾ÀÌ ±âÀú¸·À» ¹þ¾î³ªÁö ¸øÇÏ°í »óÇdz» Áï, Á¦ÀÚ¸®¿¡ ¸Ó¹°·¯ Àִ °æ¿ì¸¦ ¸»ÇÑ´Ù.
¿µ¹® carcinoma ÇÑ±Û ¾ÏÁ¾
¼³¸í   
  ¾ÏÁ¾À̶õ »óÇǼ¼Æ÷(-½ÅüÀÇ ³»ºÎ³ª ¿ÜºÎ¸¦ ½×°í Àִ Á¶Á÷À» »óÇǶó°í Çϰí, »óÇǸ¦ ÀÌ·ç°í Àִ ¼¼Æ÷¸¦ »óÇǼ¼Æ÷¶ó°í ÇÑ´Ù)ÀÇ °úµµÇÑ Áõ½Ä¿¡ÀÇÇÑ ¾Ç¼ºÁ¾¾çÀ» À̸£´Â ¸»ÀÌ´Ù.
¿µ¹® renal cell carcinoma ÇÑ±Û ÄáÆÏ¼¼Æ÷¾ÏÁ¾
¼³¸í   
  ÄáÆÏ¿¡ »ý±ä ¿ø½ÃÄáÆÏÁ¶Á÷¿¡¼­ ¹ß»ýÇÑ ¾Ï. ÁַΠ¿ø½Ã¼¼´¢°üÁ¶Á÷¿¡¼­ ¹ß»ýÇÑ´Ù. ´ëÇ¥ÀûÀΠ¼¼Æ÷Á¶Á÷ÇüÀº ¿°»ö½Ã ¼¼Æ÷ÁúÀÌ ¸¼°Ô ºñ¾îº¸À̴ ¸¼Àº¼¼Æ÷¾ÏÁ¾ÀÌ´Ù. Ä¡·á´Â ¼ö¼ú°ú Ç×¾ÏÈ­Çпä¹ýÀ̸砾ÆÁÖ µå¹°Áö¸¸ ÀúÀý·Î ³´´Â °æ¿ìµµ Àִ °ÍÀ¸·Î º¸°íµÇ¾î ÀÖ´Ù.
¿µ¹® squamous cell carcinoma ÇÑ±Û ÆíÆò¼¼Æ÷¾ÏÁ¾
¼³¸í   
  ÆíÆò¼¼Æ÷ ±â¿øÀÇ ¾ÏÀ¸·Î¼­, ÆíÆò¼¼Æ÷°¡ Àִ ¾î¶² °÷¿¡¼­µç ¹ß»ý°¡´ÉÇÔ. µû¶ó¼­ ½Äµµ¾Ï, ÇǺξÏ, Æó¾Ï, ÀڱþϠµîÀÌ ¿©±â¿¡ ÇØ´çµÈ´Ù. Æ¯È÷ ÇǺξÏÀº ¸¹Àº Àڿܼ±Á¶»ç¿¡ ÀÇÇØ »ý±â´Â ±¤¼±°¢È­Áõ¿¡¼­ ¹ß»ý°¡´ÉÇÏ´Ù. º´¸®Á¶Á÷ÇÐÀû Æ¯¼ºÀ¸·Î¼­ °¢ÁúÀ» »ý¼ºÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • carcinoma
    ¾ÏÁ¾
  • carcinoma in situ
    Á¦ÀÚ¸®¾ÏÁ¾
  • corpus carcinoma
    ÀڱøöÅë¾ÏÁ¾, ÀÚ±ÃüºÎ¾ÏÁ¾
  • duct carcinoma
    °ü¾ÏÁ¾
  • duct cell carcinoma
    °ü¼¼Æ÷¾ÏÁ¾
  • eccrine carcinoma
    ¿¡Å©¸°¾ÏÁ¾
  • embryonal carcinoma
    ¹è¾Æ¾ÏÁ¾
  • epidermoid carcinoma
    Ç¥ÇǸð¾ç¾ÏÁ¾
  • follicular carcinoma
    °©»ó»ù¼ÒÆ÷¾ÏÁ¾, ¼ÒÆ÷¾ÏÁ¾
  • giant cell carcinoma
    °Å´ë¼¼Æ÷¾ÏÁ¾
  • glandular carcinoma
    »ù¾ÏÁ¾, ¼±¾ÏÁ¾
  • granulosa cell carcinoma
    °ú¸³¼¼Æ÷¾ÏÁ¾
  • hepatocellular carcinoma
    °£¼¼Æ÷¾ÏÁ¾
  • invasive carcinoma
    ħ½À¾ÏÁ¾
  • islet cell carcinoma
    ¼¶¼¼Æ÷¾ÏÁ¾
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • anaplastic carcinoma
    ¿ªÇü¼º¾ÏÁ¾
  • basal cell carcinoma
    ¹Ù´Ú¼¼Æ÷¾ÏÁ¾, ±âÀú¼¼Æ÷¾ÏÁ¾
  • follicular carcinoma
    °©»ó»ù¼ÒÆ÷¾ÏÁ¾, ¼ÒÆ÷¾ÏÁ¾
  • invasive carcinoma
    ħ½À¾ÏÁ¾
  • medullary carcinoma
    ¼ÓÁú¾ÏÁ¾, ¼öÁú¾ÏÁ¾
  • neuroendocrine carcinoma
    ½Å°æ³»ºÐºñ¾ÏÁ¾
  • occult breast carcinoma
    ÀáÀçÀ¯¹æ¾ÏÁ¾
  • papillary carcinoma
    À¯µÎ¾ÏÁ¾
  • papillary thyroid carcinoma
    À¯µÎ°©»ó»ù¾ÏÁ¾
  • signet ring cell carcinoma
    ¹ÝÁö¼¼Æ÷¾ÏÁ¾
  • small cell carcinoma
    ¼Ò¼¼Æ÷¾ÏÁ¾
  • squamous cell carcinoma
    ÆíÆò¼¼Æ÷¾ÏÁ¾
  • squamous cell in situ carcinoma
    ÆíÆò¼¼Æ÷»óÇdz»¾ÏÁ¾, ÆíÆò¼¼Æ÷¾ÏÁ¾
  • transitional cell carcinoma
    ÀÌÇ༼Æ÷¾ÏÁ¾
  • tubular carcinoma
    °ü¾ÏÁ¾
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • comedo carcinoma
    (¢¡comedocarcinoma) ¸éÆ÷¾ÏÁ¾
  • corpus carcinoma
    ÀڱøöÅë¾ÏÁ¾, ÀÚ±ÃüºÎ¾ÏÁ¾
  • duct carcinoma
    °ü¾ÏÁ¾
  • duct cell carcinoma
    °ü¼¼Æ÷¾ÏÁ¾
  • eccrine carcinoma
    ¿¡Å©¸°¶¡»ù¾ÏÁ¾
  • embryonal carcinoma
    ¹è¾Æ¾ÏÁ¾
  • epidermoid carcinoma
    (¢¡squamous cell) ÆíÆò¼¼Æ÷¾ÏÁ¾
  • follicular carcinoma
    °©»ó»ù¼ÒÆ÷¾ÏÁ¾, ¼ÒÆ÷¾ÏÁ¾
  • giant cell carcinoma
    °Å´ë¼¼Æ÷¾ÏÁ¾
  • glandular carcinoma
    (¢¡adenocarcinoma) »ù¾ÏÁ¾
  • granulosa cell carcinoma
    °ú¸³¼¼Æ÷¾ÏÁ¾
  • hepatocellular carcinoma
    °£¼¼Æ÷¾ÏÁ¾
  • inflammatory carcinoma
    ¿°Áõ¾ÏÁ¾
  • intraepithelial carcinoma
    »óÇdz»¾ÏÁ¾, Ç¥ÇǼӾÏÁ¾
  • invasive carcinoma
    ħ½À¾ÏÁ¾
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • giant cell carcinoma
    °Å¼¼Æ÷¾ÏÁ¾
  • glandular carcinoma
    ¼±¾ÏÁ¾(¼±¾ÏÁ¾).
  • glassy cell carcinoma of cervix
    À¯¸®¾ç ¼¼Æ÷ ÀڱðæºÎ¾Ï
  • granular basal cell carcinoma
    °ú¸³ ±âÀú¼¼Æ÷¾Ï
  • granulosa cell carcinoma
    (³­¼Ò)°ú¸³¸·¼¼Æ÷ ¾ÏÁ¾(Õ°áµÎ¨í£Ø¯á¬øà ðþ).
  • hepatocellular carcinoma
    °£¼¼Æ÷¼º ¾Ï
  • hepatocellular carcinoma
    °£¼¼Æ÷¾ÏÁ¾(ÊÜá¬øàäßðþ)
  • pigmented basal cell carcinoma
    »ö¼ÒÄ§Âø ±âÀú¼¼Æ÷¾Ï
  • pilomatrix carcinoma
    ¸ð¹ß±âÁú ¾Ï(Á¾)
  • postcricoid carcinoma
    ÈÄÀ±(»ó)¾ÏÁ¾
  • primary bronchogenic carcinoma
    ¿ø¹ß(¼º)±â°üÁö¾Ï
  • primary carcinoma
    ¿ø¹ß¾ÏÁ¾(ê«Û¡äßðþ)
  • primary cutaneous adenocystic carcinoma
    ¿ø¹ß¼º ÇǺΠ¼±³¶Á¾¼º¾Ï
  • primary hepatic carcinoma
    ¿ø¹ß(¼º) °£¾ÏÁ¾(ê«Û¡(àõ) ÊÜäßðþ)
  • prostate carcinoma
    Àü¸³¼±¾ÏÁ¾(îñí¡àÍäßðþ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • adnexal carcinoma
    ºÎ¼Ó±â(ݾáÕÐï) ¾Ï
  • adrenal carcinoma
    ºÎ½Å¾ÏÁ¾
  • aggressive basal cell carcinoma
    ħ½À ±âÀú¼¼Æ÷¾Ï(Ðñî¼á¬øàäß)
  • apocrine gland carcinoma
    ¾ÆÆ÷Å©¸°¼±(~ àÍ) ¾Ï(Á¾)(äß(ðþ))
  • arsenical basal cell carcinoma
    ºñ¼Ò¼º(Ý÷áÈàõ) ±âÀú¼¼Æ÷¾Ï
  • arsenical carcinoma
    ºñ¼Ò¼º(Ý÷áÈàõ) ¾Ï(Á¾)
  • bartholin gland carcinoma
    ¹Ù¸£Å縰¼±¾Ï
  • basal cell carcinoma
    ±âÀú¼¼Æ÷¾Ï
  • basal cell carcinoma
    ±âÀú¼¼Æ÷¾ÏÁ¾ (¡­äßðþ)
  • basal cell carcinoma, of penis
    À½°æ ±âÀú¼¼Æ÷¾ÏÁ¾
  • basosquamous cell carcinoma
    ±âÀú ÆíÆò¼¼Æ÷ ¾Ï(Á¾)
  • bladder carcinoma
    ¹æ±¤¾ÏÁ¾
  • breast carcinoma
    À¯¹æ¾Ï
  • breast,carcinoma
    ¾ÏÁ¾(äßðþ)
  • breast,carcinoma colloid or mucinous
    Á¡¾×¼º (ïÄäûàõ)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • median paralysis dose
    Á¤Áß ¸¶ºñ·®(ïáñ騫ÝöÕá)
  • median tissue culture dose
    Á¤ÁßÁ¶Á÷¹è¾ç·®(ïáñéðÚòÄÛÆå×Õá)
  • median toxic dose
    Á¤Áß µ¶¼º·®(ïáñéÔ¸àõÕá)
  • minimum hemagglutinating dose
    ÃÖ¼ÒÇ÷±¸ÀÀÁý·®(õÌá³úìϹëêó¢Õá)
  • minimum hemolytic dose
    ÃÖ¼Ò¿ëÇ÷·®(õÌá³éÁúìÕá)
  • minbimum lethal dose
    ÃÖ¼ÒÄ¡»ç·®(õÌá³öÈÞÝÕá)
  • permissible dose
    Çã¿ë·®(úÉé»Õá)
  • priming dose
    ÀÏÂ÷󸮿뷮(ìéó­ô¥×âéÄÕá)
  • radiation absorbed dose
    ¹æ»ç¼± Èí¼ö·®(Û¯ÞÒàÊýåâ¥Õá)
  • radiation dose
    ¹æ»ç¼±·®(Û¯ÞÒàÊÕá)
  • threshold dose
    ¹®ÅÎ ¼±·®(àÊÕá)
  • tissue culture infectious dose
    Á¶Á÷¹è¾ç °¨¿°·® (ðÚòÄÛÆå×ÊïæøÕá)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • undifferentiated carcinoma
    ¹ÌºÐÈ­¾ÏÁ¾
  • air dose
    °øÁß¼±·®, °ø±âÁß¼±·®
  • cumulative dose
    ÁýÀû¼±·®, ´©ÀûÁ¶»ç·®, ´©Àû¿ë·®, Ãàô¿ë·®
  • curative dose
    ġȿ·®
  • depth dose
    ½ÉºÎ¼±·®
  • dose rate
    ¼±·®·ü
  • fatal dose
    Ä¡»ç·®
  • half lethal dose
    ¹ÝÄ¡»ç·®
  • LD = lethal dose
    Ä¡»ç·®
  • lethal dose [=LD]
    Ä¡»ç·®
  • maintenance dose
    À¯Áö¿ë·®
  • maximal acceptable dose
    ÃÖ´ëÇã¿ë¼±·®
  • maximum permissible dose [=MPD]
    ÃÖ´ëÇã¿ë(¼±)·®
  • median lethal dose
    50%Ä¡»ç·®, Æò±ÕÄ¡»ç·®
  • midbreast dose
    À¯¹æÁß¾ÓÁ¶»ç¼±·®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MD Doctor of Medicine [Lat. Medicinae Doctor]; magnesium deficiency; main duct; maintenance dose; major...
MID maximum inhibiting dilution; mesioincisodistal; midinfarct dementia; minimum infective dose; minimum...
NSD Nairobi sheep disease; neonatal staphylococcal disease; neurosecretory dysfunction; night sleep depr...
TCD tapetochoroidal dystrophy; T-cell depletion; thermal conductivity detector; tissue culture dose; tra...
EC effective concentration; ejection click; electrochemical; electron capture; embryonal carcinoma; eme...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
DEF Dose Effect Factor
DI Dose Intensity
DMF Dose Modifying Factor
DRF Dose Reduction Factor
DAP Dose area product
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • dose limit
    ¼±·® Çѵµ, ¼±·® Á¦ÇÑ
  • dose modifying factor
    ¼±·® ¼ö½Ä °è¼ö
  • dose profile
    ¼±·® Ãø¸éµµ
  • dose rate effect
    ¼±·®À² È¿°ú
  • dose rate variation
    ¼±·®·ü º¯È­
  • dose response relationship
    ¹æ»ç¿ë·® ¹ÝÀÀ °ü°è, ¿ë·® ¹ÝÀÀ °ü°è
  • dose-effect relationship
    ¼±·® ¿µÇâ °ü°è
  • dose-equivalent limit
    ¼±·® ´ç·® Çѵµ
  • dose-response curve
    ¿ë·® ¹ÝÀÀ °î¼±
  • dose-volume histogram
    ¼±·® üÀû È÷½ºÅä±×¶÷, ¼±·® üÀûÇ¥
  • effective dose 50%
    Áß°£ À¯È¿·®, 50% À¯È¿·®
    µ¿¹°¿¡ µ¶¼Ò³ª ¾à¹° Åõ¿© ½Ã, 50%ÀÇ µ¿¹°¿¡¼­ À¯È¿ÇÏ´Ù°í ÃßÁ¤µÇ´Â ¿ë·®.
  • equivalent dose
    µî°¡ ¼±·®
  • equivalent uniform dose
    µî°¡ ±ÕÁú ¼±·®
  • erythema dose
    Èï¹Ý ¼±·®
  • exposure dose
    Á¶»ç·®
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
minimal reacting dose The minimal dose of a toxic substance causing a reaction, as manifested in the skin of a series of susceptible test animals; the assay is based on the development of a characteristic, minimal but definite, "standard," focal inflammation (congestion and oedema, induration, degenerative changes, and desquamation of epidermal cells).
(05 Mar 2000)
cumulative dose The total dose resulting from repeated exposures to radiation of the same part of the body or of the whole body.
(05 Mar 2000)
curative dose The quantity of any substance required to effect the cure of a disease or that will correct the manifestations of a deficiency of a particular factor in the diet, effective dose used with therapeutically applied compounds.
Synonym: therapeutic dose.
(05 Mar 2000)
preventive dose The smallest amount of any substance that will prevent occurrence of symptoms of a disease or the consequences of a lack of a particular factor in the diet.
(05 Mar 2000)
high dose tolerance The induction of tolerance by exposure to high doses of antigen.
(05 Mar 2000)
sensitizing dose In experimental anaphylaxis, the antigenic inoculum that renders an animal susceptible (sensitive) to anaphylactic shock following a subsequent inoculum (shocking dose) of the same antigen (anaphylactogen).
(05 Mar 2000)
shocking dose In experimental anaphylaxis, the inoculum of antigen that causes anaphylactic shock in an animal sensitised by a previous inoculum (sensitizing dose) of the same antigen.
(05 Mar 2000)
skin dose The quantity of radiation delivered to the skin surface.
(05 Mar 2000)
daily dose The total amount of a remedy that is to be taken within 24 hours.
(05 Mar 2000)
depth dose The dose of radiation at a distance beneath the surface, including secondary radiation or scatter, in proportion to the dose at the surface.
(05 Mar 2000)
divided dose A definite fraction of a full dose; given repeatedly at short intervals so that the full dose is taken within a specified period, usually one day.
Synonym: fractional dose.
(05 Mar 2000)
dose 1. <pharmacology> A quantity to be administered at one time, such as a specified amount of medication.
2. <radiobiology> A general term denoting the quantity of radiation or energy absorbed. For special purposes it must be appropriately qualified. If unqualified, it refers to absorbed dose. Unit of absorbed dose is the rad. The SI unit is the gray (1 Gy = 1 J kg-1 = 100 R).
Origin: Gr. Dosis = a giving
(16 Dec 1997)
dose-effect curve This is a graph drawn to show the relationship between the dose of a drug or other chemical and the magnitude of the graded effect that it produces.
(09 Oct 1997)
dose-escalation A preliminary clinical trial in which the amount of the drug is either periodically increased or increased with each new trial arm that is added. Used to determine how a drug is tolerated in people.
(09 Oct 1997)
dose fractionation Adminstration of the total dose of radiation (radiation dosage) in parts, at timed intervals.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á